Skip to content
← All startups
Aulos Bioscience logo

Aulos Bioscience

Series B

Developer of antibody therapeutic solutions for the treatment of cancer. The company is involved in the development of IL-2 targeting antibodies that mainly known as Interleukin-2 (IL‑2) cytokine secreted by activated T-cells provides treatment solutions for solid tumors. It has a CD25 binding site that binds antibodies to the respective cancer cells.

Life Sciences · Oncology · Larkspur, United States · EST 2020

About

Developer of antibody therapeutic solutions for the treatment of cancer. The company is involved in the development of IL-2 targeting antibodies that mainly known as Interleukin-2 (IL‑2) cytokine secreted by activated T-cells provides treatment solutions for solid tumors. It has a CD25 binding site that binds antibodies to the respective cancer cells.

Institutional investors

Apple Tree Partners

Latest coverage

📰 See all funding news — keep up with the raises that set comps.

Investor directory

🗂️ Full list of active funds — filter by stage, check size, and geography.

Raising like Aulos Bioscience?

Analyze your pitch deck before your next raise.

Analyze My Deck →